Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated ...
Nektar Therapeutics (Nasdaq: NKTR) today showcased data in two presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place in Denver, CO.
Institutional Shares underperformed its benchmark, the Russell 2000 Value Index (net), during the quarter. Read more here.
MALMÖ, SE / ACCESS Newswire / March 27, 2026 / Ascelia Pharma (STO:ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that an abstract with an ...
Unlock the future of industrial data. Join our webinar to compare storage systems and build a scalable architecture that ...
April 8-12 meeting in Charlotte, NC highlights debridement, mobile wound care education, and evidence-based clinical ...
NEW YORK, March 26, 2026 /PRNewswire/ — S&P Global’s (NYSE: SPGI) first quarter 2026 results will be issued on Tuesday, April 28, 2026 via news release at approximately 7:15 a.m. Eastern Daylight Time ...
Total new-vehicle sales for March 2026, including retail and non-retail transactions, are projected to reach 1,372,877, a 11.4% decrease year-over-year, and a 11.9% increase from February 2026, ...
MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the year ended December 31, 2025, and ...
Zoonotic malaria caused by infection with the monkey parasite Plasmodium knowlesi has emerged across Southeast Asia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results